Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS

Carlo Bernasconi, E. Paolo Alessandrino, Paolo Bernasconi, Maurizio Bonfichi, Mario Lazzarino, Angelo Canevari, Guglielmo Castelli, Ercole Brusamolino, Guido Pagnucco, Carlo Castagnola

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

One hundred and five consecutive primary high-risk myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia (sAML) evolving from MDS (performance status 0-3, ECOG) entered this study. Induction chemotherapy (CT) consisted of idarubicine 12 mg/m2 i.v. on days 1 and 2, etoposide 60 mg/m2/12 h i.v. for 5 d, Ara-C 120 mR/m2/12 h i.v. for 5d (one or two courses). Patients were randomized to receive or not G-CSF (5 μg/kg/d subcutaneously 48 h after the end of CT). 52 cases underwent CT alone and 53 CT+G-CSF. The CT+G-CSF patients had a significantly shorter duration of neutropenia (8 v 16 d) with a lower incidence of infections and significantly better responses (CR+PR: 74% v 52%, P2 every 12 h for 3 d). Most CRs were clonal. At present 21 responders have relapsed (median relapse-free survival 4.5 months). Eight responders received an allo-BMT, six are alive in CR 7-57 months post-transplant. Therefore allo-BMT only increases the chance of a long survival and possible cure. In conclusion, CT+G-CSF did not prolong either CR duration or survival; the growth factor support, however, increased the number of allo-transplantable cases by inducing higher remission rates and improving clinical conditions.

Original languageEnglish
Pages (from-to)678-683
Number of pages6
JournalBritish Journal of Haematology
Volume102
Issue number3
DOIs
Publication statusPublished - 1998

Fingerprint

Myelodysplastic Syndromes
Granulocyte Colony-Stimulating Factor
Acute Myeloid Leukemia
Drug Therapy
Survival
Dilatation and Curettage
Induction Chemotherapy
Etoposide
Neutropenia
Intercellular Signaling Peptides and Proteins
Clinical Studies
Transplants
Recurrence
Incidence
Infection

Keywords

  • Chemotherapy
  • G-CSF
  • MDS
  • sAML
  • Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. / Bernasconi, Carlo; Alessandrino, E. Paolo; Bernasconi, Paolo; Bonfichi, Maurizio; Lazzarino, Mario; Canevari, Angelo; Castelli, Guglielmo; Brusamolino, Ercole; Pagnucco, Guido; Castagnola, Carlo.

In: British Journal of Haematology, Vol. 102, No. 3, 1998, p. 678-683.

Research output: Contribution to journalArticle

Bernasconi, Carlo ; Alessandrino, E. Paolo ; Bernasconi, Paolo ; Bonfichi, Maurizio ; Lazzarino, Mario ; Canevari, Angelo ; Castelli, Guglielmo ; Brusamolino, Ercole ; Pagnucco, Guido ; Castagnola, Carlo. / Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. In: British Journal of Haematology. 1998 ; Vol. 102, No. 3. pp. 678-683.
@article{5cda447ed9aa471c96509f62ad21dd07,
title = "Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS",
abstract = "One hundred and five consecutive primary high-risk myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia (sAML) evolving from MDS (performance status 0-3, ECOG) entered this study. Induction chemotherapy (CT) consisted of idarubicine 12 mg/m2 i.v. on days 1 and 2, etoposide 60 mg/m2/12 h i.v. for 5 d, Ara-C 120 mR/m2/12 h i.v. for 5d (one or two courses). Patients were randomized to receive or not G-CSF (5 μg/kg/d subcutaneously 48 h after the end of CT). 52 cases underwent CT alone and 53 CT+G-CSF. The CT+G-CSF patients had a significantly shorter duration of neutropenia (8 v 16 d) with a lower incidence of infections and significantly better responses (CR+PR: 74{\%} v 52{\%}, P2 every 12 h for 3 d). Most CRs were clonal. At present 21 responders have relapsed (median relapse-free survival 4.5 months). Eight responders received an allo-BMT, six are alive in CR 7-57 months post-transplant. Therefore allo-BMT only increases the chance of a long survival and possible cure. In conclusion, CT+G-CSF did not prolong either CR duration or survival; the growth factor support, however, increased the number of allo-transplantable cases by inducing higher remission rates and improving clinical conditions.",
keywords = "Chemotherapy, G-CSF, MDS, sAML, Survival",
author = "Carlo Bernasconi and Alessandrino, {E. Paolo} and Paolo Bernasconi and Maurizio Bonfichi and Mario Lazzarino and Angelo Canevari and Guglielmo Castelli and Ercole Brusamolino and Guido Pagnucco and Carlo Castagnola",
year = "1998",
doi = "10.1046/j.1365-2141.1998.00816.x",
language = "English",
volume = "102",
pages = "678--683",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS

AU - Bernasconi, Carlo

AU - Alessandrino, E. Paolo

AU - Bernasconi, Paolo

AU - Bonfichi, Maurizio

AU - Lazzarino, Mario

AU - Canevari, Angelo

AU - Castelli, Guglielmo

AU - Brusamolino, Ercole

AU - Pagnucco, Guido

AU - Castagnola, Carlo

PY - 1998

Y1 - 1998

N2 - One hundred and five consecutive primary high-risk myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia (sAML) evolving from MDS (performance status 0-3, ECOG) entered this study. Induction chemotherapy (CT) consisted of idarubicine 12 mg/m2 i.v. on days 1 and 2, etoposide 60 mg/m2/12 h i.v. for 5 d, Ara-C 120 mR/m2/12 h i.v. for 5d (one or two courses). Patients were randomized to receive or not G-CSF (5 μg/kg/d subcutaneously 48 h after the end of CT). 52 cases underwent CT alone and 53 CT+G-CSF. The CT+G-CSF patients had a significantly shorter duration of neutropenia (8 v 16 d) with a lower incidence of infections and significantly better responses (CR+PR: 74% v 52%, P2 every 12 h for 3 d). Most CRs were clonal. At present 21 responders have relapsed (median relapse-free survival 4.5 months). Eight responders received an allo-BMT, six are alive in CR 7-57 months post-transplant. Therefore allo-BMT only increases the chance of a long survival and possible cure. In conclusion, CT+G-CSF did not prolong either CR duration or survival; the growth factor support, however, increased the number of allo-transplantable cases by inducing higher remission rates and improving clinical conditions.

AB - One hundred and five consecutive primary high-risk myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia (sAML) evolving from MDS (performance status 0-3, ECOG) entered this study. Induction chemotherapy (CT) consisted of idarubicine 12 mg/m2 i.v. on days 1 and 2, etoposide 60 mg/m2/12 h i.v. for 5 d, Ara-C 120 mR/m2/12 h i.v. for 5d (one or two courses). Patients were randomized to receive or not G-CSF (5 μg/kg/d subcutaneously 48 h after the end of CT). 52 cases underwent CT alone and 53 CT+G-CSF. The CT+G-CSF patients had a significantly shorter duration of neutropenia (8 v 16 d) with a lower incidence of infections and significantly better responses (CR+PR: 74% v 52%, P2 every 12 h for 3 d). Most CRs were clonal. At present 21 responders have relapsed (median relapse-free survival 4.5 months). Eight responders received an allo-BMT, six are alive in CR 7-57 months post-transplant. Therefore allo-BMT only increases the chance of a long survival and possible cure. In conclusion, CT+G-CSF did not prolong either CR duration or survival; the growth factor support, however, increased the number of allo-transplantable cases by inducing higher remission rates and improving clinical conditions.

KW - Chemotherapy

KW - G-CSF

KW - MDS

KW - sAML

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=7344222651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7344222651&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1998.00816.x

DO - 10.1046/j.1365-2141.1998.00816.x

M3 - Article

C2 - 9722293

AN - SCOPUS:7344222651

VL - 102

SP - 678

EP - 683

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -